

## Supplementary data

**Table 1. Inclusion and exclusion criteria for the original randomized study previously published (Holmgren et al 2012b)**

<p><b>Inclusion criteria</b></p> <p>Age 30–65 Duration of pain &gt; 6 months Unsatisfactory results &gt; 3 months of conservative treatment Scheduled for ASD <i>At least 3 positive tests of the following:</i></p> <ul style="list-style-type: none"><li>– Neer impingement sign</li><li>– Hawkins Kennedy impingement sign</li><li>– Jobe supraspinatus test</li><li>– Patte's manoeuvre</li></ul> <p><b>Exclusion criteria</b></p> <p><i>Clinically verified:</i></p> <ul style="list-style-type: none"><li>– Shoulder instability</li><li>– Symptoms from the cervical spine</li><li>– Fibromyalgia</li><li>– Frozen shoulder</li><li>– Suspected polyarthritis</li><li>– Rheumatoid arthritis</li><li>– Pseudoparalysis</li><li>– Acromioclavicular tenderness</li><li>– A corticosteroid injection during the last 3 months for the current problem</li></ul> <p><i>Radiologically verified:</i></p> <ul style="list-style-type: none"><li>– Malignancies</li><li>– Osteoarthritis of the glenohumeral joint</li><li>– Previous fracture or surgery in the shoulder complex on the affected side</li><li>– Os acromiale</li><li>– Acromioclavicular arthritis</li></ul>
--

**Table 3. Mean clinical scores and standard deviation (SD) at baseline, 3-month, 1-year (previously published data) and new 5-year follow-up scores. Groups according to the original randomization and patients' decision about surgery**

	C-M score <sup>a</sup>	DASH score <sup>b</sup>	EQ-5D <sup>c</sup>	EQ-VAS <sup>d</sup>	VAS rest <sup>e</sup>	VAS activity	VAS night
<b>Baseline (n = 97)</b>							
Specific non-operated (n = 41)	50 (14)	27 (12)	0.7 (0.7)	69 (14)	16 (20)	60 (20)	45 (29)
Specific operated (n = 10)	42 (18)	40 (18)	0.5 (0.3)	64 (20)	48 (28)	65 (26)	12 (16)
Control non-operated (n = 17)	54 (12)	27 (13)	0.7 (0.1)	64 (17)	19 (15)	67 (22)	33 (28)
Control operated (n = 29)	37 (13)	40 (15)	0.6 (0.3)	61 (22)	26 (22)	66 (20)	43 (31)
<b>3-month follow-up (n = 97)</b>							
Specific non-operated (n=41)	78 (13)	11 (10)	0.9 (0.1)	75 (20)	7 (11)	17 (18)	8 (15)
Specific operated (n = 10)	53 (22)	32 (18)	0.7 (0.2)	65 (22)	19 (19)	51 (29)	36 (28)
Control non-operated (n = 17)	75 (14)	12 (15)	0.9 (0.1)	78 (20)	6 (14)	20 (20)	12 (22)
Control operated (n = 29)	40 (16)	39 (14)	0.6 (0.2)	28 (27)	53 (23)	36 (26)	36 (26)
<b>1-year follow-up (n=95)<sup>f</sup></b>							
Specific non-operated (n = 38)	84 (14)	7 (9)	0.9 (0.1)	87 (11)	2 (7)	15 (22)	11 (18)
Specific operated (n = 12)	79 (12)	16 (13)	0.8 (0.1)	76 (19)	8 (3)	28 (24)	15 (23)
Control non-operated (n = 16)	85 (13)	5 (6)	0.9 (0.1)	86 (13)	5 (16)	12 (18)	11 (19)
Control operated (n = 29)	76 (18)	13 (15)	0.8 (0.2)	73 (20)	4 (13)	18 (21)	14 (21)
<b>5-year follow-up (n = 91)<sup>g</sup></b>							
Specific non-operated (n = 33)	91 (10) <sup>e</sup>	7 (10)	0.9 (0.1)	84 (12)	4 (10)	9 (11)	8 (16)
Specific operated (n = 14)	84 (17)	15(17)	0.8 (0.1)	82 (11)	6 (10)	31 (37)	25 (35)
Control non-operated (n = 16)	89 (14)	10(15)	0.7 (0.1)	75 (18)	4 (11)	11 (16)	7 (19)
Control operated (n = 28)	80 (15)	16(18)	0.6 (0.3)	83 (11)	11 (19)	19 (25)	16 (25)

<sup>a</sup> C-M Score= Constant- Murley Shoulder Assessment Score 0-100 points (100 points= maximum shoulder function).

<sup>b</sup> DASH score=Disabilities of the Arm Shoulder and Hand score 0-100 in which 0 is the best shoulder function

<sup>c</sup> EQ-5D index 1- (-0.59) in which -0.59 is the lowest health-related quality of life.

<sup>d</sup> EQ-VAS (0-100) in which 0 is the lowest health status.

<sup>e</sup> Pain VAS (Visual Analogue Scale) 0-100 mm in which 100 is the worst imaginable pain.

<sup>f</sup> 2 patient lost between 3-month and 1-year follow-up.

<sup>g</sup> 4 patient lost between 1-year and 5-year follow-up.

<sup>e</sup> n = 32, 1 patient missing data